baclofen has been researched along with Cirrhosis, Liver in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the baclofen group, the frequency of muscle cramps decreased significantly after 1 and 3 months of treatment (P<0." | 9.22 | Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, AA; Elkhalawany, W; Shehab El-Din, I; Soliman, S; Zakaria, S, 2016) |
| "Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis." | 9.12 | Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007) |
| "In the baclofen group, the frequency of muscle cramps decreased significantly after 1 and 3 months of treatment (P<0." | 5.22 | Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, AA; Elkhalawany, W; Shehab El-Din, I; Soliman, S; Zakaria, S, 2016) |
| "Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis." | 5.12 | Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. ( Abenavoli, L; Addolorato, G; Caputo, F; Cardone, S; D'Angelo, C; Ferrulli, A; Gasbarrini, G; Haber, PS; Leggio, L; Mirijello, A; Vonghia, L; Zambon, A, 2007) |
| " The usual side effects such as drowsiness were frequent (22%) but no serious adverse events (AEs) or overt encephalopathy related to baclofen was reported." | 1.91 | Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study. ( Alqallaf, S; Barrault, C; Behar, V; Bourcier, V; Cadranel, JF; Costentin, C; Hagege, H; Jung, C; Labarriere, D; Lamote-Chaouche, I; Laugier, J; Le Gruyer, A; Lison, H; Ripault, MP; Thevenot, T, 2023) |
| "Baclofen has been trialled for AUD in cirrhosis and appears to be effective." | 1.72 | Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice. ( Cheng, A; Habtemariam, Z; Kelleher, C; Lewis, H; Lovendoski, J; Strathie, K; Tyson, LD, 2022) |
| "The treatment of alcohol dependence (AD) is a complex activity as the variables are numerous; however, those which must necessarily be taken into account are the type of AD, the internal comorbidities and the presence of any psychiatric comorbidity." | 1.43 | Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy. ( Borro, P; Leone, S; Testino, G, 2016) |
| "But the role of the GABAB receptor in liver fibrosis has never been reported." | 1.39 | Γ-aminobutyric acid B receptor improves carbon tetrachloride-induced liver fibrosis in rats. ( Fan, W; Feng, K; He, X; Ma, X; Shi, B; Wei, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Tyson, LD | 2 |
| Cheng, A | 1 |
| Kelleher, C | 1 |
| Strathie, K | 1 |
| Lovendoski, J | 1 |
| Habtemariam, Z | 1 |
| Lewis, H | 2 |
| Giri, S | 1 |
| Sundaram, S | 1 |
| Vannier, AGL | 1 |
| Shay, JES | 1 |
| Fomin, V | 1 |
| Patel, SJ | 1 |
| Schaefer, E | 1 |
| Goodman, RP | 1 |
| Luther, J | 1 |
| Barrault, C | 2 |
| Alqallaf, S | 2 |
| Lison, H | 2 |
| Lamote-Chaouche, I | 2 |
| Bourcier, V | 2 |
| Laugier, J | 2 |
| Thevenot, T | 2 |
| Labarriere, D | 2 |
| Ripault, MP | 2 |
| Le Gruyer, A | 2 |
| Costentin, C | 2 |
| Behar, V | 2 |
| Hagege, H | 2 |
| Jung, C | 2 |
| Cadranel, JF | 2 |
| Fan, W | 1 |
| Shi, B | 1 |
| Wei, H | 1 |
| Ma, X | 1 |
| He, X | 1 |
| Feng, K | 1 |
| Borro, P | 1 |
| Leone, S | 1 |
| Testino, G | 1 |
| Henry, ZH | 1 |
| Northup, PG | 1 |
| Elfert, AA | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Zakaria, S | 1 |
| Shehab El-Din, I | 1 |
| Elkhalawany, W | 1 |
| Abd-Elsalam, S | 1 |
| Addolorato, G | 1 |
| Leggio, L | 1 |
| Ferrulli, A | 1 |
| Cardone, S | 1 |
| Vonghia, L | 1 |
| Mirijello, A | 1 |
| Abenavoli, L | 1 |
| D'Angelo, C | 1 |
| Caputo, F | 1 |
| Zambon, A | 1 |
| Haber, PS | 1 |
| Gasbarrini, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis[NCT05724485] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| A Pilot Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking[NCT01076283] | Phase 2 | 14 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Maintaining Alcohol Abstinence in Alcoholic Patients With Liver Cirrhosis: Efficacy and Safety of Baclofen Administration in a Randomized Double Blind Controlled Study[NCT00525252] | Phase 1/Phase 2 | 86 participants | Interventional | 2003-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Whether baclofen, as compared to active placebo, results in lower quantity of alcohol consumed during the Alcohol Self-Administration (ASA).~Consistent with O'Malley et al. 2002, the ASA paradigm allows to use a fixed-dose (the priming drink), followed by a 2-hour free-choice phase when subjects may choose to drink or not up to 8 mini-drinks. Participants receive a monetary compensation of $3 dollars per each mini-drink not consumed; therefore the amount of minidrinks consumed during the 2-hour sessions ranges 0-8, and the monetary compensation ranges $0-24. The quantity of alcohol consumed during the free-choice session is expressed as standard drinking unit, where a standard drink unit contains about 14 grams of pure alcohol (about 0.6 fluid ounces or 1.2 tablespoons)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
| Intervention | standard drinking units (Mean) |
|---|---|
| Baclofen | 0.17 |
| Cyproheptadine | 1.43 |
"Whether baclofen, as compared to active placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink [as measured by the Alcohol Urge Questionnaire (AUQ)] during the Cue Reactivity.~The Alcohol Urge Questionnaire (AUQ) consists of eight statements about the respondent's feelings and thoughts about drinking as they are completing the questionnaire (i.e., right now). The respondent is asked to respond to each statement about alcohol craving via a 7-item Likert scale ranging from strongly disagree to strongly agree. Each item is scored on a 1 to 7 scale (Strongly Disagree = 1 and Strongly Agree = 7). Items 2 and 7 are reverse scored. A total score is computed by summing the item scores and ranges from 8 (lowest craving value) to 56 (highest craving value). Higher scores reflect greater craving (i.e. worse outcome)." (NCT01076283)
Timeframe: approximately 8 days after drug administration
| Intervention | units on a scale (Mean) |
|---|---|
| Baclofen | 22.5 |
| Cyproheptadine | 19.4 |
2 trials available for baclofen and Cirrhosis, Liver
| Article | Year |
|---|---|
Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis.
Topics: Adult; Baclofen; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Muscle Cramp; Muscle Relaxants, | 2016 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
Topics: Alcoholism; Baclofen; Double-Blind Method; Female; GABA Agonists; Humans; Liver Cirrhosis; Male; Mid | 2007 |
9 other studies available for baclofen and Cirrhosis, Liver
| Article | Year |
|---|---|
Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Retrospective Studies | 2022 |
Acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Nal | 2022 |
Response to 'acamprosate better than baclofen for alcohol use disorder in cirrhosis: fact or myth?'
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis | 2022 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
Topics: Alcohol Drinking; Alcoholism; Baclofen; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Psychia | 2023 |
Γ-aminobutyric acid B receptor improves carbon tetrachloride-induced liver fibrosis in rats.
Topics: Actins; Animals; Baclofen; Biomarkers; Blotting, Western; Carbon Tetrachloride; Drug Administration | 2013 |
KASL clinical practice guidelines: management of alcoholic liver disease.
Topics: Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Baclofen; Disulfiram; Fatty Liver, | 2013 |
Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy.
Topics: Acamprosate; Alcohol Deterrents; Alcoholics; Alcoholism; Baclofen; Carcinoma, Hepatocellular; Drug C | 2016 |
Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative.
Topics: Baclofen; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2016 |